3.1 Baseline patient characteristics and study design
Baseline patient and tumor characteristics of 108 mRCC patients are
presented according to gender in Table 1. The whole study population
received targeted therapy (pazopanib, n=64; sunitinib, n=44). Clear cell
histology (72.2%) was the most common subtype. During a median
follow-up of 22 months (range: 2–102 months), 38 (35.2%) patients died
and 28 (25.9%) patients were considered obese (BMI of ≥30 kg
/m2). According to the IMDC criteria [4]; of the
108 patients, 9 (8.3%) were in favorable-risk group, 66 (61.1%) in
intermediate-risk group and 33 (30.5%) in poor-risk group.
Body composition parameters differed between men and women listed in
Table 2. While median baseline total adipose tissue index (TATI) and
subcutaneous adipose tissue index (SATI) were significantly higher in
females than males, median baseline skeletal muscle index (SMI) was
higher in males (P<0.001). None of the second and change
measures of all VBC parameters exhibited a significant difference among
males and females and also none of the VBC parameters was associated
with pathologic features of RCC including histological subtype, tumor
grade, or tumor size (data not shown)